- AbbVie’s adjusted EPS forecast for the fiscal year surpasses estimates, ranging from $11.19 to $11.23.
- The company’s third-quarter results revealed an adjusted EPS of $2.95, higher than the estimated $2.85.
- The net revenue for the third quarter was $13.93 billion, exceeding the estimated $13.69 billion.
- Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox – Cosmetic, Juvederm, Botox – Therapeutic, Vraylar, Ubrelvy, and Creon all surpassed revenue estimates.
- The adjusted gross margin was 83.5%, slightly below the estimated 83.8%.
- The adjusted operating margin was 46.7%, also slightly below the estimated 47%.
- Adjusted R&D expenses for the year were $1.72 billion, a 7% increase from the previous year, marginally above the estimated $1.71 billion.
- AbbVie has raised its 2024 Adjusted Diluted EPS Guidance Floor from $10.70 to $11.00, excluding any impact related to Acquired IPR&D and Milestones Expense.
- The company does not expect the adjusted diluted EPS for the full year 2024 to be below $11.00 per share.
- There will be a 4.7% increase in the 2024 dividend, starting with the dividend payable in February 2024.
Abbvie Inc on Smartkarma
According to the latest research reports from the independent analyst network Smartkarma, Abbvie Inc. has seen positive results in the past quarter. Analysts from Baptista Research have reported that Abbvie Inc. surpassed expectations in terms of revenue and earnings, driven by the success of Skyrizi and Rinvoq in immunology. Both treatments are now approved across ten significant indications and are projected to generate more than $11 billion in combined revenue this year.
Baptista Research has also noted that Abbvie Inc. delivered a decent result in the first quarter of the year with revenues above Wall Street expectations and earnings in line with the analyst consensus. Growth rates for Skyrizi and Rinvoq in the first quarter were in line with the company’s estimation for the entire year. Despite the recent failure of the CytomX collaboration, analysts remain bullish about Abbvie Inc.’s prospects in the coming year.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
AbbVie Inc. is a research and development company that produces pharmaceutical drugs for specialty therapeutic areas. According to Smartkarma Smart Scores, AbbVie Inc. has a long-term outlook that is looking good. The company has earned a Momentum score of 5 out of 5, indicating that it is doing well in terms of its growth prospects. It also has a Dividend score of 3 out of 5 and a Growth score of 3 out of 5, showing that it is performing well in terms of dividend payments and overall growth. AbbVie Inc. also has a Resilience score of 2 out of 5 and a Value score of 2 out of 5, indicating that it is still working to increase its resilience and value.
Overall, AbbVie Inc. is in a good position for the long-term. The company is performing well in terms of growth, dividend payments, and its outlook. Although it still has some room to improve in terms of resilience and value, it is still doing well overall. With its high Momentum score, AbbVie Inc. is in a good place for the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
